Leverkusen, Germany

Joachim Ippen



Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Cologne, DE (1981 - 1986)
  • Leverkusen, DE (1990 - 2003)

Company Filing History:


Years Active: 1981-2003

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Inventor Spotlight: Joachim Ippen

Introduction

Joachim Ippen is a notable inventor hailing from Leverkusen, Germany. With a prolific career marked by five patents, Ippen has made significant contributions to the fields of pharmacology and medicinal chemistry. His work focuses on innovations that aim to improve treatments for lipid metabolism disorders and antifungal therapies.

Latest Patents

Among Joachim Ippen's latest patents is a remarkable invention involving the combination of cerivastatin and fibrates. This invention addresses the prophylaxis and treatment of disorders related to lipid metabolism. Another notable patent features antimycotically active substituted 2-aminothiazoles, which showcases potential applications in combating fungal infections.

Career Highlights

Throughout his career, Joachim Ippen has been affiliated with prestigious companies such as Bayer Aktiengesellschaft and BASF Aktiengesellschaft. His tenure at these organizations has allowed him to leverage their resources and expertise, furthering his innovative projects and enhancing his contributions to the scientific community.

Collaborations

Ippen has collaborated with esteemed colleagues like Klaus Schaller and Bernd Baasner. These partnerships have fostered a creative environment that encourages knowledge sharing and innovative thinking, driving advancements in their respective fields.

Conclusion

Joachim Ippen's achievements as an inventor reflect his dedication to enhancing pharmaceuticals that tackle critical health issues. His patents not only demonstrate his innovative capabilities but also highlight the collaborative spirit that propels scientific advancements. The impact of his work will continue to resonate in the medical community for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…